What if you could drink your COVID-19 vaccine instead of rolling up your sleeve? No needle — just a “swish and swallow,” and your new immunity is down the hatch.
You might be able to within the next couple of years, as researchers expand their focus onto mucosal vaccines, which include nasal or inhaled vaccines as well as “swish and swallow” oral vaccines such as QYNDR, which completed its phase 1 clinical trial and is currently waiting on more funding to conduct the more detailed, advanced trials that could actually bring the vaccine to market.
The QYNDR vaccine is pronounced “kinder,” because it’s a softer way to deliver a vaccine, says Kyle Flanigan, founder of QYNDR’s maker, US Specialty Formulations. Promising clinical trial results from New Zealand offer hope that QYNDR will be a viable option for protection against the string of COVID-19 variants circulating. The findings have not been peer-reviewed yet.
But to advance it to the additional clinical trials needed to take it to review and market, they need funding from investors. This week, Flanigan was in San Francisco at the JP Morgan Healthcare Conference trying to get that funding.
Read More